Unity Biotechnology’s (UBX) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Unity Biotechnology (NASDAQ:UBX – Get Rating) in a research note released on Thursday morning, Benzinga reports. The brokerage currently has a $35.00 target price on the stock.

A number of other research analysts also recently issued reports on the company. Mizuho cut their price objective on Unity Biotechnology from $80.00 to $12.00 and set a buy rating for the company in a research note on Wednesday, November 16th. HC Wainwright reiterated a buy rating and set a $10.00 price objective on shares of Unity Biotechnology in a research note on Wednesday, February 15th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of Buy and a consensus target price of $34.25.

Unity Biotechnology Trading Down 6.7 %

NASDAQ UBX opened at $3.78 on Thursday. Unity Biotechnology has a 52 week low of $2.09 and a 52 week high of $18.50. The company has a quick ratio of 6.12, a current ratio of 4.92 and a debt-to-equity ratio of 0.16. The company has a 50-day moving average price of $4.31 and a 200-day moving average price of $3.86.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Arete Wealth Advisors LLC bought a new position in Unity Biotechnology in the 4th quarter worth approximately $140,582,970,000. Prime Capital Investment Advisors LLC bought a new position in Unity Biotechnology in the 4th quarter worth approximately $31,000. Jane Street Group LLC bought a new position in Unity Biotechnology in the 4th quarter worth approximately $37,000. Schonfeld Strategic Advisors LLC bought a new position in Unity Biotechnology in the 4th quarter worth approximately $38,000. Finally, Dimensional Fund Advisors LP bought a new position in Unity Biotechnology in the 4th quarter worth approximately $83,000.

About Unity Biotechnology

(Get Rating)

Unity Biotechnology, Inc operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.